
Sign up to save your podcasts
Or


Recent studies have shown that smoking cannabis can improve some of the debilitating symptoms of inflammatory bowel disease, but the overall results are still inconclusive. Based on our current understanding, what is the impact of medical cannabis on IBD? Shira Johnson and Dr. Arun Swaminath, a practicing gastroenterologist at Northwell Health and Director of the Inflammatory Bowel Diseases Program at Lenox Hill Hospital, discuss the research of using cannabis to treat IBD.
Pain management is an unmet need for patients with IBD, or inflammatory bowel disease. How can we help them manage this excruciating symptom safely and effectively? Dr. Matthew Coates, a physician scientist at Penn State Health Gastroenterology, joins Dr. Jennifer Caudle to identify what causes chronic pain and how we can best serve our patients.
Here to share his insights on difficult cases in Crohn’s disease is Dr. Eytan Mor from the Rabin Medical Center in Israel. Dr. Mor defines for us what a difficult case in Crohn’s disease looks like and the various treatment options that are available.
Published August 27, 2020
Nutrition plays an important role in inflammatory bowel disease, but it’s important to instill in patients the understanding that even though a healthy diet can help reduce symptoms, it doesn’t mean that the disease itself has improved. Here to share how he talks about nutrition with his patients and other key management strategies like the low FODMAP diet is Dr. James Lindsay, Professor of Inflammatory Bowel Disease at Barts Health in London.
Published August 27, 2020
Inflammatory bowel disease in pediatric patients is not as uncommon as you may think. Dr. Stacy Kahn, Assistant Professor of Pediatrics at Boston Children’s Hospital, shares her experience with healthy diet plans, preparing families for transition, and more.
Published August 7, 2020
When patients with inflammatory bowel disease find that certain treatments aren’t working for them, should we resort to surgical options? Tune in to hear Dr. Amy Lightner, Assistant Professor of Surgery and Immunology at the Cleveland Clinic, share her experience and key considerations.
Published August 7, 2020
Tune in to hear Dr. Britt Christensen from Royal Melbourne Hospital in Melbourne, Australia discuss difficult cases she’s encountered and the steps she takes to care for her patients with ulcerative colitis.
Published August 7, 2020
There are multiple resources at hand to help guide you toward a career in clinical research, and here to share them along with his overall experience in the field is Dr. Sid Singh, clinical gastroenterologist at UC San Diego.
Published August 7, 2020
A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice
Marina Liso, Stefania De Santis, Giulio Verna, Manuela Dicarlo, Maria Calasso, Angelo Santino, Isabella Gigante, Rajaraman Eri, Sathuwarman Raveenthiraraj, Anastasia Sobolewski, Valeria Palmitessa, Antonio Lippolis, Mauro Mastronardi, Raffaele Armentano, Grazia Serino, Maria De Angelis, Marcello Chieppa
Background: Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC), is a multifactorial disorder characterized by chronic inflammation and altered gut barrier function. Dysbiosis, a condition defined by dysregulation of the gut microbiome, has been reported in patients with IBD and in experimental models of colitis. Although several factors have been implicated in directly affecting gut microbial composition, the genetic determinants impacting intestinal dysbiosis in IBD remain relatively unknown.
Methods: We compared the microbiome of normal, uninflamed wild-type (WT) mice with that of a murine model of UC (ie, Winnie strain). Winnie mice possess a missense mutation in Muc2 that manifests in altered mucus production as early as 4 weeks of …
Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s
Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD
Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX.
Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic window. The reactive strategy only did so at the time of a flare.
Results: The proactive strategy led to fewer flares than the …
From the publisher's feed